PDF(Pubmed)
Abstract：
Atrial remodelling, defined as a change in atrial structure, promotes atrial fibrillation (AF). Bone morphogenetic protein 10 (BMP10) is an atrial-specific biomarker released to blood during atrial development and structural changes. We aimed to validate whether BMP10 is associated with AF recurrence after catheter ablation (CA) in a large cohort of patients.
We measured baseline BMP10 plasma concentrations in AF patients who underwent a first elective CA in the prospective Swiss-AF-PVI cohort study. The primary outcome was AF recurrence lasting longer than 30 s during a follow-up of 12 months. We constructed multivariable Cox proportional hazard models to determine the association of BMP10 and AF recurrence. A total of 1112 patients with AF (age 61 ± 10 years, 74% male, 60% paroxysmal AF) was included in our analysis. During 12 months of follow-up, 374 patients (34%) experienced AF recurrence. The probability for AF recurrence increased with increasing BMP10 concentration. In an unadjusted Cox proportional hazard model, a per-unit increase in log-transformed BMP10 was associated with a hazard ratio (HR) of 2.28 (95% CI 1.43; 3.62, P < 0.001) for AF recurrence. After multivariable adjustment, the HR of BMP10 for AF recurrence was 1.98 (95% CI 1.14; 3.42, P = 0.01), and there was a linear trend across BMP10 quartiles (P = 0.02 for linear trend).
The novel atrial-specific biomarker BMP10 was strongly associated with AF recurrence in patients undergoing CA for AF.
NCT03718364; https://clinicaltrials.gov/ct2/show/NCT03718364.
We measured baseline BMP10 plasma concentrations in AF patients who underwent a first elective CA in the prospective Swiss-AF-PVI cohort study. The primary outcome was AF recurrence lasting longer than 30 s during a follow-up of 12 months. We constructed multivariable Cox proportional hazard models to determine the association of BMP10 and AF recurrence. A total of 1112 patients with AF (age 61 ± 10 years, 74% male, 60% paroxysmal AF) was included in our analysis. During 12 months of follow-up, 374 patients (34%) experienced AF recurrence. The probability for AF recurrence increased with increasing BMP10 concentration. In an unadjusted Cox proportional hazard model, a per-unit increase in log-transformed BMP10 was associated with a hazard ratio (HR) of 2.28 (95% CI 1.43; 3.62, P < 0.001) for AF recurrence. After multivariable adjustment, the HR of BMP10 for AF recurrence was 1.98 (95% CI 1.14; 3.42, P = 0.01), and there was a linear trend across BMP10 quartiles (P = 0.02 for linear trend).
The novel atrial-specific biomarker BMP10 was strongly associated with AF recurrence in patients undergoing CA for AF.
NCT03718364; https://clinicaltrials.gov/ct2/show/NCT03718364.
摘要：
目的：心房重塑，定义为心房结构的变化，促进心房颤动（AF）。骨形态发生蛋白10（BMP10）是心房发育和结构变化过程中释放到血液中的心房特异性生物标志物。我们旨在验证BMP10是否与导管消融术（CA）后房颤复发相关。
结果：在前瞻性Swiss-AF-PVI队列研究中，我们测量了接受首次选择性CA的AF患者的基线BMP10血浆浓度。主要结果是在12个月的随访中持续超过30s的房颤复发。我们构建了多变量Cox比例风险模型来确定BMP10与房颤复发的相关性。总共1112例房颤患者(年龄61±10岁,74%男性,60%阵发性房颤)纳入我们的分析。在12个月的随访中，374例患者（34%）出现房颤复发。房颤复发的概率随着BMP10浓度的增加而增加。在未经调整的Cox比例风险模型中，对数转化的BMP10每单位增加与房颤复发的风险比(HR)为2.28(95%CI1.43;3.62,P<0.001)相关.经过多变量调整后，BMP10对房颤复发的HR为1.98(95%CI1.14;3.42,P=0.01),并且在BMP10四分位数之间存在线性趋势（线性趋势P=0.02）。
结论：新型心房特异性生物标志物BMP10与接受CA治疗的房颤患者房颤复发密切相关。
背景：NCT03718364;https://clinicaltrials.gov/ct2/show/NCT03718364。
结果：在前瞻性Swiss-AF-PVI队列研究中，我们测量了接受首次选择性CA的AF患者的基线BMP10血浆浓度。主要结果是在12个月的随访中持续超过30s的房颤复发。我们构建了多变量Cox比例风险模型来确定BMP10与房颤复发的相关性。总共1112例房颤患者(年龄61±10岁,74%男性,60%阵发性房颤)纳入我们的分析。在12个月的随访中，374例患者（34%）出现房颤复发。房颤复发的概率随着BMP10浓度的增加而增加。在未经调整的Cox比例风险模型中，对数转化的BMP10每单位增加与房颤复发的风险比(HR)为2.28(95%CI1.43;3.62,P<0.001)相关.经过多变量调整后，BMP10对房颤复发的HR为1.98(95%CI1.14;3.42,P=0.01),并且在BMP10四分位数之间存在线性趋势（线性趋势P=0.02）。
结论：新型心房特异性生物标志物BMP10与接受CA治疗的房颤患者房颤复发密切相关。
背景：NCT03718364;https://clinicaltrials.gov/ct2/show/NCT03718364。
